The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.45
Bid: 11.30
Ask: 11.60
Change: 0.20 (1.72%)
Spread: 0.30 (2.655%)
Open: 11.65
High: 11.80
Low: 11.80
Prev. Close: 11.60
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Poolbeg wins patents; RA swings to loss

Thu, 26th May 2022 10:51

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Poolbeg Pharma PLC, up 17% at 7.00 pence, 12-month range 4.13p-13.30p. The London-based pharmaceutical company has been granted patents by the US Patent & Trademark Office related to its POLB 001 and POLB 002 molecules. The former is used to treat influenza, while the latter is an RNA-based immunotherapy for respiratory virus infections. "The company is continuing working with its patent advisors to broaden and expand the POLB 001 and POLB 002 patent families," Poolbeg says.

----------

AIM - LOSERS

----------

RA International Group PLC, down 12% at 21.15p, 12-month range 21.10p-70.00p. The remote site services provider posts an annual revenue decline and a swing to loss. Revenue in 2021 falls 15% to USD54.6 million from USD64.4 million. RA swings to a pretax loss of USD32.2 million from a USD6.6 million profit. RA's bottom line was hit by USD31.5 million in non-underlying charges relating to its Mozambique project. "Investors will be aware that this area was subject to an insurgency attack in March 2021 and, as at the time of these results, the local situation had not yet stabilised sufficiently to see sizable commercial activity restarting. We are working hard to realise value from our investments made relating to this project, which will support our cash position," RA says. The stock hit its 12-month low on Thursday.

----------

Coro Energy PLC, down 8.7% at 0.32p, 12-month range 0.22p-0.52p. The company has suspended its Sillaro well in Italy as hot weather there seen an increase of moisture in gas production. "The company is assessing various solutions to this problem and expects this issue to be resolved shortly," Coro says.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Mar 2024 11:10

Poolbeg Pharma to be granted US patent

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.

Read more
19 Feb 2024 14:22

Director dealings: Poolbeg Pharma co-founder ups stake

(Sharecast News) - Poolbeg Pharma revealed on Monday that chairman Cathal Friel had acquired 830,000 ordinary shares in the AIM-listed biopharmaceutical company.

Read more
15 Feb 2024 16:02

TRADING UPDATES: Diversified Energy offers dividend alternative

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
12 Feb 2024 19:44

TRADING UPDATES: Katoro Gold launches fundraising, eyes board shake-up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
12 Feb 2024 14:37

Poolbeg upbeat on research into potential drug market

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery.

Read more
17 Jan 2024 13:58

Poolbeg Pharma hails POLB 001'S potential to treat CRS

(Alliance News) - Poolbeg Pharma PLC on Wednesday noted "promising" results for POLB 001's potential in treating cancer immunotherapy-induced cytokine release syndrome.

Read more
20 Dec 2023 20:00

TRADING UPDATES: K3 Business says cash balances ahead of forecast

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Dec 2023 13:54

Poolbeg makes promising progress with RSV programme

(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.

Read more
21 Nov 2023 14:39

TRADING UPDATES: Poolbeg hails approval; EDX links with Thermo Fisher

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
9 Nov 2023 16:57

IN BRIEF: Poolbeg Pharma appoints former Amryt executives to team

Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Appoints a number of former executives of Amryt Pharma PLC to its leadership team. Poolbeg's Chair, Cathal Friel, co-founded both Poolbeg and Amryt Pharma.

Read more
17 Oct 2023 10:49

Poolbeg Pharma shares up on metabolic drug collaboration agreement

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has agreed to collaborate with an unnamed Nasdaq-listed biopharmaceutical company for the development of an optimised oral drug to treat a metabolic condition.

Read more
2 Oct 2023 14:20

EARNINGS AND TRADING: Kingswood cuts outlook; Poolbeg in patent joy

(Alliance News) - The following is a round-up of updates by London-listed companies, issued last week and not separately reported by Alliance News:

Read more
22 Sep 2023 20:37

TRADING UPDATES: Braemar investigation to end; Marula reports delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday, Thursday and Wednesday and not separately reported by Alliance News:

Read more
20 Sep 2023 12:16

Poolbeg gets notice of a new Japan patent

(Sharecast News) - Clinical-stage biopharmaceutical company Poolbeg Pharma announced the receipt of a notice of allowance from the Japanese Patent Office for its Immunomodulator I patent application on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.